Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06144697 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 267
- Enrollment target
NCT06144697 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 267 participants.
The verdict
NCT06144697, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 267 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate safety, tolerability, drug and food effects on relative bioavailability of BMS-986465 and its active derivative BMS-986464 in healthy participants and healthy participants of Japanese ethnicity.
Interventions
- OTHER Placebo
- DRUG Famotidine
- DRUG Pegasys
- DRUG BMS-986465
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2024-01-29 |
| Est. Completion | 2024-10-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06144697
The ClinicalTrials.gov registry entry for NCT06144697 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 267 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT06144697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06144697 about?
NCT06144697 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants". The purpose of this study is to evaluate safety, tolerability, drug and food effects on relative bioavailability of BMS-986465 and its active derivative BMS-986464 in healthy participants and healthy participants of Japanese ethnicity.
What is the current status of trial NCT06144697?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 267 participants. The study started on 2024-01-29. Estimated completion is 2024-10-16.
What interventions are being tested in trial NCT06144697?
The interventions under investigation include: Placebo (OTHER), Famotidine (DRUG), Pegasys (DRUG), BMS-986465 (DRUG).
Who is sponsoring clinical trial NCT06144697?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.